作者
F. Stephen Hodi,Steven O’Day,David F. McDermott,Robert Weber,Jeffrey A. Sosman,John B.A.G. Haanen,René González,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaübel,Gerald P. Linette,David Hogg,Christian Ottensmeier,Célèste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jing Tian,Michael Yellin,G. Nichol,Axel Hoos,Walter J. Urba
摘要
An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.
cctv18
shinysparrow
个性的紫菜
gjww
wk990240
寻道图强
iVANPENNY
敬老院1号
凤凰
农业土壤
不安青牛
SOLOMON
柯一一
罗_
Maimai
SCINEXUS
benben
寻寻觅觅呢
newfat
pluto
皖公网安备34019202002308
